CAS: 872365-14-5; 2-(2-Methyl-1-(4-(Methylsulfonyl)-2-(Trifluoromethyl)Benzyl)-1H-Pyrrolo[2,3-B]Pyridin-3-yl)Acetic Acid

该化合物是一种选择性的 plasglandin D2(PGD2) 受体敌体,具体针对CRTH2(在T2细胞上表现的化学吸引受体-混合分子分子)受体,正在调查其在炎症和过敏条件下的潜在治疗应用,如哮喘和外皮皮炎,抑制CRTH2受体,阻断PGD2下游效应,包括乙酰菌素招募和T2细胞活化,这是第2类炎症的主要驱动因素;其口服生物利用率和定向机制为调节过敏途径提供了有希望的方法,对更广泛的免疫抑制剂的安全和效率具有潜在优势;临床研究继续评估其在呼吸道和皮肤紊乱精医学中的作用.

结构式图片

上下游产品

Methyl 2-(2-Methyl-1-(4-(Methylsulfonyl)-2-(Trifluoromethyl)Benzyl)-1H-Pyrrolo[2,3-B]Pyridin-3-yl)Acetate
(1Ar,12Bs)-8-Cyclohexyl-5-[[[(Dimethylamino)Sulfonyl]Amino]Carbonyl]-1,12B-Dihydro-11-Methoxycycloprop[d]Indolo[2,1-A][2]Benzazepine-1A(2H)-Carboxylic Acid 928843-71-4
Ethyl (R)-1-Cyclopropyl-8-Difluoromethoxy-7-(1-Methyl-2-Tritylisoindolin-5-yl)-1,4-Dihydro-4-Oxoquinoline-3-Carboxylate 194804-45-0
2-<2-<(2-Hydroxyethyl)Amino>Ethyl>-5-<<2-<(2-Hydroxyethyl)Amino>Ethyl>Amino>-7-(Phenylmethoxy)Anthra<1,9-Cd>Pyrazol-6(2H)-One 88303-59-7
曲西瑞宾 Triciribine 35943-35-2
纳布啡 Nalbuphine 20594-83-6
2-(2-甲基-1H-吡咯并[2,3-B]吡啶-3-基)乙酸甲酯 (2-Methyl-1H-Pyrrolo[2,3-B]Pyridin-3-yl)Acetic Acid Methyl Ester 7546-52-3
{8-氟-2-[4-(3-甲氧基苯基)-1-哌嗪基]-3-[2-甲氧基-5-(三氟甲基)-苯基]-3,4-二氢-4-喹唑啉基}-乙酸甲酯 Methyl 2-[8-Fluoro-3-[2-Methoxy-5-(Trifluoromethyl)Phenyl]-2-[4-(3-Methoxyphenyl)Piperazin-1-Yl]-3,4-Dihydroquinazolin-4-Yl] Acetate 791117-40-3
2-甲基-1H-吡咯并[2,3-B]吡啶-3-乙酸 2-(2-Methyl-1H-Pyrrolo[2,3-B]Pyridin-3-yl)Acetic Acid 7546-50-1
1-[(2'-[(乙氧羰基)氧基]脒基)[1,1-联苯基]-4-基)甲基]-2-乙氧基-1H-苯并咪唑-7-甲酸甲酯 Azilsartan Methyl Ester 147403-52-9

合成工艺路线路线简述

  • 872366-74-0 = 872365-14-5
    反应条件:1.1 Reagents: Sodium Hydroxide Solvents: Water; 4 H,50 °C1.2 Reagents: Sulfuric Acid Solvents: Water; Ph 9 - 10
    标题:Using A Johnson-Claisen Rearrangement Strategy To Construct Azaindoles - A Streamlined And Concise Route For The Commercial Process Of Fevipiprant
    作者:Mathes,Christian; Et Al
    参考文献:European Journal Of Organic Chemistry 日期:2021 卷标:2021(31) 页码:4490-4494]

    1638892-78-0 = 872365-14-5
    反应条件:1.1 Reagents: Potassium Carbonate,Triphenylphosphine Catalysts: Palladium Diacetate,Cuprous Iodide Solvents: Ethanol,Toluene; Rt -> 75 °C; 12 H,75 °C2.1 Catalysts: Pivalic Acid,N-Acetyl-L-Cysteine Solvents: Methyl Isobutyl Ketone; 4 H,155 °C2.2 Catalysts: Pivalic Acid Solvents: Methyl Isobutyl Ketone; 15 H,1.1 - 1.5 Bar,145 °C2.3 Reagents: Sodium Hydroxide Solvents: Water; 4 H,50 °C2.4 Reagents: Sulfuric Acid Solvents: Water; Ph 9 - 10
    标题:Using A Johnson-Claisen Rearrangement Strategy To Construct Azaindoles - A Streamlined And Concise Route For The Commercial Process Of Fevipiprant
    作者:Mathes,Christian; Et Al
    参考文献:European Journal Of Organic Chemistry 日期:2021 卷标:2021(31) 页码:4490-4494]

    872366-74-0 = 872365-14-5
    反应条件:1.1 Reagents: Sodium Hydroxide,Methyl 2-Methyl-7-[[4-(Methylsulfonyl)-2-(Trifluoromethyl)Phenyl]Methyl]-7H-Pyrr... Solvents: Acetone,Water; Overnight,Rt1.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 3,Rt
    标题:Discovery Of Fevipiprant (Nvp-Qaw039),A Potent And Selective Dp2 Receptor Antagonist For Treatment Of Asthma
    作者:Sandham,David A.; Et Al
    参考文献:Acs Medicinal Chemistry Letters 日期:2017 卷标:8(5) 页码:582-586]

    1445-45-0 + 2092997-91-4 = 872365-14-5
    反应条件:1.1 Catalysts: Pivalic Acid,N-Acetyl-L-Cysteine Solvents: Methyl Isobutyl Ketone; 4 H,155 °C1.2 Catalysts: Pivalic Acid Solvents: Methyl Isobutyl Ketone; 15 H,1.1 - 1.5 Bar,145 °C1.3 Reagents: Sodium Hydroxide Solvents: Water; 4 H,50 °C1.4 Reagents: Sulfuric Acid Solvents: Water; Ph 9 - 10
    标题:Using A Johnson-Claisen Rearrangement Strategy To Construct Azaindoles - A Streamlined And Concise Route For The Commercial Process Of Fevipiprant
    作者:Mathes,Christian; Et Al
    参考文献:European Journal Of Organic Chemistry 日期:2021 卷标:2021(31) 页码:4490-4494]

    13534-99-1 + 1215310-75-0 = 872365-14-5
    反应条件:1.1 Reagents: P-Toluenesulfonic Acid Solvents: Toluene; 16 H,145 °C; 145 °C -> 50 °C1.2 Reagents: Sodium Borohydride Solvents: Methanol; 2 H; 4 H,Heated1.3 Reagents: Acetic Acid Solvents: Water; 10 Min,Ph 6 - 11; 1 H2.1 Reagents: Potassium Carbonate,Triphenylphosphine Catalysts: Palladium Diacetate,Cuprous Iodide Solvents: Ethanol,Toluene; Rt -> 75 °C; 12 H,75 °C3.1 Catalysts: Pivalic Acid,N-Acetyl-L-Cysteine Solvents: Methyl Isobutyl Ketone; 4 H,155 °C3.2 Catalysts: Pivalic Acid Solvents: Methyl Isobutyl Ketone; 15 H,1.1 - 1.5 Bar,145 °C3.3 Reagents: Sodium Hydroxide Solvents: Water; 4 H,50 °C3.4 Reagents: Sulfuric Acid Solvents: Water; Ph 9 - 10
    标题:Using A Johnson-Claisen Rearrangement Strategy To Construct Azaindoles - A Streamlined And Concise Route For The Commercial Process Of Fevipiprant
    作者:Mathes,Christian; Et Al
    参考文献:European Journal Of Organic Chemistry 日期:2021 卷标:2021(31) 页码:4490-4494]

    1215323-17-3 = 872365-14-5
    反应条件:1.1 Reagents: Phosphorus Tribromide Solvents: Diethyl Ether; 10 Min,0 °C; 0 °C -> Rt; Overnight,Rt2.1 Reagents: Cesium Carbonate,Sulfuric Acid Magnesium Salt (1:1) Solvents: Acetone; 10 Min,Rt -> Reflux; Reflux -> Rt2.2 Solvents: Acetone; 10 Min,Rt; 4 H,Reflux; Overnight,Rt; 2 H,Reflux; Reflux -> Rt; 16 H,Rt -> Reflux3.1 Reagents: Sodium Hydroxide,Methyl 2-Methyl-7-[[4-(Methylsulfonyl)-2-(Trifluoromethyl)Phenyl]Methyl]-7H-Pyrr... Solvents: Acetone,Water; Overnight,Rt3.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 3,Rt
    标题:Discovery Of Fevipiprant (Nvp-Qaw039),A Potent And Selective Dp2 Receptor Antagonist For Treatment Of Asthma
    作者:Sandham,David A.; Et Al
    参考文献:Acs Medicinal Chemistry Letters 日期:2017 卷标:8(5) 页码:582-586
3-(2-氧代丙基)-氯化吡啶置于三乙基硅烷,Potassium Carbonate,间氯过氧苯甲酸,Bromo-Tris(1-Pyrrolidinyl)Phosphonium Hexafluorophosphate,三氟乙酸体系中,用 二氯甲烷 作为反应溶剂,化学反应 6.0H,反应生成 非维匹仑
参考文献:一种哮喘药物fevipiprant的简洁合成方法
标题:一种哮喘药物fevipiprant的简洁合成方法
摘要:本发明公开一种哮喘药物fevipiprant的简洁合成方法,所述方法包括以下步骤d:使化合物4反应反应生成fevipiprant.本发明方法是以1‑(3‑吡啶基)‑2‑丙酮为原料,氧化反应生成吡啶氮氧化物,在温和条件下关环得到7‑氮杂吲哚母核,该方法合成步骤少,工艺简单,反应条件温和,生产成本低,无过渡金属催化,整个合成不用任何保护基,开拓了较为简单的四步法制备fevipiprant的方法.

海关参考信息

专利信息


专利号:CN-108484595-B
优先权日:2018-02-27
标 题:Simple synthesis method of asthma medicine Fevipiprant

专利号:CN-108484595-A
优先权日:2018-02-27
标 题:A concise synthesis method of asthma medicine Fevipiprant
杭州氟药药业有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.fluoropharm.cn
电话:0571-85586753;13336034509👤
📞 杭州氟药药业有限公司⚠️参考联系方式

电话: 0571-85586753;13336034509
邮件:sales@fluoropharm.com
网址: http://www.fluoropharm.cn
地址:浙江省杭州市滨江区西兴街道江陵路88号
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

浙江省杭州市滨江区西兴街道江陵路88号
⚠️ 未注册 · 未认证企业
注册入口 备注: 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别. 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: White C, Wright A, Brightling C. Fevipiprant in the treatment of asthma. Expert Opin Investig Drugs. 2018 Feb;27(2):199-207. doi: 10.1080/13543784.2018.1432592. Epub 2018 Jan 30. 14(5):e24641. doi: 10.7759/cureus.24641.
3: Kao CC, Parulekar AD. Spotlight on fevipiprant and its potential in the treatment of asthma: evidence to date. J Asthma Allergy. 2019 Jan 3;12:1-5. doi: 10.2147/JAA.S167973.
4: Brightling C, Kulkarni S, Lambrecht BN, Sandham D, Weiss M, Altman P. The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant. Pulm Pharmacol Ther. 2021 Jun;68:102030. doi: 10.1016/j.pupt.2021.102030. Epub 2021 Apr 4. 149(5):1587-1589. doi: 10.1016/j.jaci.2022.03.001. Epub 2022 Mar 15. 9(1):43-56. doi: 10.1016/S2213-2600(20)30412-4. Epub 2020 Sep 24.

合成参考文献


参考文献:10.1007/s12098-018-2686-0
摘要:Maitra A. Severe Asthma: Challenges and Pitfalls in Management. Indian J Pediatr. 2018 Sep;85(9):763–72. doi: 10.1007/s12098-018-2686-0.
参考文献:10.4049/jimmunol.2001245
摘要:Chen W, Luo J, Ye Y, Hoyle R, Liu W, Borst R, Kazani S, Shikatani EA, Erpenbeck VJ, Pavord ID, Klenerman P, Sandham DA, Xue L. The Roles of Type 2 Cytotoxic T Cells in Inflammation, Tissue Remodeling, and Prostaglandin (PG) D2 Production Are Attenuated by PGD2 Receptor 2 Antagonism. J Immunol. 2021 Jun 01;206(11):2714–24.
摘要:S55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | DOI:10.5281/zenodo.3247749
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知